Overview

ARX788 in Breast Cancer With Low Expression of HER2

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
A Phase 2 Study of ARX788 in unresectable and/or metastatic breast cancer with low expression of HER2.
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University